biotech venture creation

Antigenix Therapeutics Inc, a Syridex Bio Company, is a biotechnology company developing antibody-based therapies, including antibody-drug conjugate (ADC) therapies, for cancers resistant to current treatments. Its patented antibody technology targets a cancer-specific marker to attack tumors while sparing healthy cells. The company develops monoclonal antibody-based therapies targeting novel, tumor-specific cell surface proteins and is preparing a pre-clinical program toward IND submission.

Read more

antibody-drug conjugate developmentclinical advancementpre-clinical program developmenttranslational medicine